RYTM Rhythm Pharmaceuticals, Inc.
RYTM Rhythm Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-17 1 neutral converging
POC $99.34 · VWAP $99.65 · +15.8% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
RYTM Price Structure
Loading timeframes…
Peers
Every watchlist RYTM belongs to, members best 30-day change first — RYTM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
Reported the quarter ending 2026-03-31: revenue $60M, diluted EPS $-0.83, net income $-56M (SEC filing). Across the print the stock moved +12.9% (close before → first close after).
full note →Against street estimates
How RYTM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about RYTM from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21 · last pull reported an error, so these may be older than they look
- Rhythm Pharmaceuticals (RYTM) Institutional Ownership 2026
- Rhythm Pharmaceuticals Q1 2026 results show strong growth | RYTM Quarterly Report (10-Q)
- Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To ...
- Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Navigating A 63.13% Potential Upside In Biotechnology
- Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript | Seeking Alpha
RYTM research tape
14 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.